Ruxolitinib (ruxo) is a potent JAK1/2 inhibitor used for the treatment of high-risk myelofibrosis and Fedratinib (fed) is a JAK2 specific inhibitor currently in Phase III trials for high-risk myelofibrosis [22]. Here, JAK1 is linked to myelofibrosis.